The Black Keys
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
BEHL Harvesting.
Does anyone know if BEHL can harvest algae?
The harvesting program they supposedly had set up was just jury rigged.
Cool, I hope they are able to formaly answer shareholders questions at some piont and time during or after the event.
Check thier website; blogs & forums. And reread the pr's: a lot of intentions and desires
we haven't seen a statement re the mj conferance that dick&bob are alledgedly speaking at…
nore do we know the status or terms or developments of the sfio, intends to develop joint venture.
A lot more questions than answers....IMO
transfer agent is now gagged and took a message. To me that = dilution or transfering of a/s shares to freely traded.
If anyone Happens to get in touch with managment, please be sure to ask them about headquaters and the whereabouts of the cbis 'analitical lab'
looks like the renewed confidance is capped under a quarter a share, maybe we get wind from the office soon, I hope…
Dilution? Has anyone checked and posted our share structure lately? I might have missed it…
!¡$Go HESG$¡!
OMG! Green Volume! This is great! I hope we break out of 'the box' please let us break out
The float must be so thin....I can't belive we held gains thru the week and for all of today. WOW
if we get solid news next week; I might have to stfu...
Nice Work Pumpers
Pleasantly Suprised....
I must have my monitor upside down?
The three of them can't command maintain and steer this vessel from port to port! They can't even allot time to administrate and clean up thier website! This is grim news : I hope they have other plans ....
This will greatly reduce exposure and fester suspisions of R. Dabney & Co massaging the terminal.
Would love some mainstream headline press for Friday
if not profit taking will resume - IMO
WOW volume, WTF?
I think we have seen the majority of profit taking from the lows of around .04, until we leg up
to the next upward resistance.
Tomorrow will tell us a lot.
I really hope profit taking friday is met with a substantial operations update
if nothing substantial or a silly fluff release is made I think we will start to wash out.
...some people that got this around .04-.07 few days ago might see this as an opportunity to sell and jump back in when it bottoms again thats all. Its already slowed abd will probably be .08-.10 at close....
I agree - if the float continues to get absorbed and the company isn't selling
and traders retain high targets, all bets are off, we will all be in the green.
We need confidance from the inside for traders to raise thier abitions.
C MJ; They are behind schedule.
the cost of revenue should tell you how long MRNJ will be around or how about how many shares they need to churn out...
How MANY dollars has it historically taken NRNJ to produce 1 dollar?
How MANY dollars does it currently cost MRNJ to produce 1 dollar?
How MANY dollars does management foresee it taking to produce 1 dollar in 2011? 2012?
That would be nice to know.....I have other cookies to crumble tonight
I might be wrong, but if you double check how much we have historically spent & what we are currently spending on that aspect of this operation, and consider that that cost isn't going to decrease; you would conclude that more efficient & fruitful means are available.
We are surviving on this, It should be considered of the upmost importance and equally important as it parallels the brand with recognition and trust. You should pick up a bottle of Cannabis Science Medicine and pick up the phone to our Cannabis Science Investor Relation firm and you should feel the same confidence.
True Story; this latest released statement was crafted and proofed with better results - IMO - it bolstered eroding support from this latest influx of new investors
A great move would be contracting with a solid, tried and true Investor Relation Firm; no hard feelings Mark. You have done a fine job considering your relative experience & the fact that you landed this gig because of your contact and friendship with Mr. Cowan. You have carried us further than you thought you could and you should be considered for an enhanced position - imo
Moving Investor Relations out of house to a heavy hitting firm should be strongly considered by the CBIS officers as it will insulate from the past corruptive speculative shenanigans offing legitimacy and guaranteeing a broader healthier more retail based group of investors.
Pictures do speak a thousand words
Sorry guys I just don't feel all your momo from this release. I do walk away with that release with 2 good bits and a nice realization of their FDA submittal anticipation
1.This strain and its formulated products will be available for dispensary sale in the next quarter.
This is the first I've seen of market branding or positioning CS as a brand with a specific strain. Good job
2. Cannabis Science and its colleagues have been assembling a petition to the Colorado Department of Health and Environment to gain acceptance for medical cannabis use for PTSD under the state regulations.
This is nice to see our company positioning itself on a frontline. Good job
And it was very nice to let us know who is consulting them in the conceptual stages of FDA applications.
is in the planning phase with the CBR International Group…..
Our goal is to coordinate clinical partnerships and patient care with our standardized product line in Colorado, and to gather data that supports the use of cannabis extracts for this indication before pursuing a new drug application.
Welcome to all the new & up and comming CBIS bagholders¡!
When you get ahold of our IR contact mr. Freidman please relay these questions I sent; they seem to have overlooked me....
I would like to purchase more common stock, averaging down on my substantially negative equity position with Cannabis Science
but before I do that, I would greatly appreciate a response to these simple questions regarding our publicly traded comany
Because of the sensitivity of some of these questions and to protect my interest I have blind carbon copied my council and have poised these questions to the trading public on an open forum.
Your timely response either private or public will be appreciated.
Questions for CBIS Officers:
1. Does CBIS have any intent or plan of action for capitalizing on California's upcoming Proposition19 vote should it pass as expected?
if so, please describe in specifics.
If not why have you ignored this market; California has paved the way to greatness with it's unofficial most profitable & largest export (ahead of even wine, women and song) being Marijuana. CBIS officers have claimed to be industry leaders with massive foresight and industry knowledge. Please explain why we are not poised within California.
2. In June of 2010 CBIS publicly released the acquisition of Montana Pain Management. Two months later you publicly released that CBIS would pursue legal action against Mr. Rosio for deliberately breaching a non disclosure/non-circumvention agreement.
Have you exhausted this pursuit?
Does Dr. Morales have any interest with CBIS?
Does Mr. Rosio have any interest with CBIS?
3. On feb. 18, 2010, The Vancouver Sun Reported: Banned promoter (Ray Dabney) may soon be back touting penny stocks
Read more: http://www.vancouversun.com/life/Banned+promoter+soon+back+touting+penny+stocks/2579722/story.html#ixzz10n0ZamGq
Is this the same Ray Dabney that Richard Cowan admits to receiving equity / stock advise from?
Is Ray Dabney involved with CBIS?
If so in what capacity?
4. On July 8, 2010 CBIS publicly released the "Acquisition of New 9,500 Square foot Denver facility for researching, Developing, Testing and Producing Medical Cannabis. Since that release shareholders have not received an update regarding this space.
Has CBIS executed a lease or purchase agreement?
If so please offer further details regarding this space, its condition, and if or if not CBIS is operating or improving this space for operations.
Specifics here would be welcomed regarding this as shareholders have sent numerous inquiries that have gone unanswered.
5. A shareholder has recently calculated that CBIS has swapped some 33,888,295 shares of common stock between Aug of 2009 and May 19, 2010
How many shares of common stock has CBIS issued in the period from May 19, 2010 to our current date?
Do the officers of CBIS foresee sustainability at any point, from revenues or profit or activities other than the issuing of shares, that will relief the issuing and dilution of our common stock?
6. Because of the transfer of Title, Ticker, Ownership, and cusip: It is difficult to conclude who or what entity maintains majority interest.
It is assumed that K&D Equity maintains majority interest.
Please clarify;
Who (or what combined group) maintains majority interest in CBIS?
7. On Aug 18, 2010 multiple statements were released by CBIS
A. regarding Rockbrook: Please describe our current working relationship and operations and wether officers are pleased with the agreement that was reached.
Has Rockbrook produced funds per the agreement?
Do we expect to continue our relationship with Rockbrook?
B. regarding Smokefree Innotec: It was publicly released that CBIS was entering into a joint venture agreement with SFIO to develop and market smoke free vaporized medical cannabis pharmaceutical products.
Has the Joint Venture been executed? If so what are the basic terms
Has any progress been made with these smoke free vaporized medical cannabis pharmaceutical products?
If so to what extent?
Thank you for your time and service
The shareholders and Trading Public on our Open Forum are excited for you response.
Respectfully,
& the lack of responce to the late interest of CBIS Stock going into Prop19
from the CBIS office tells me that they don't care about shareholders.
Has anyone checked the S/S today?
Has anyone spoken to mark?
Did they clean up the web site?
They've done nothing worthy of a news release going into Prop19?
IMO, the company has a lot to answer to and all this hypothetical prop19 hype is erroding faster than newbe investors can transfer money.
printed untold shares in the past 4-5 months
undisclosed terms regarding SFIO joint venture
undisclosed progress and definition of full latitude w/ rockbrook
undisclosed progress on two failed attempts at securing office/lab space
undisclosed progress on FDA jibber jabber
undisclosed involvment of fined and barred (from SEC) advisors
undisclosed dividend progress
and that just what I can think That they could PR of late, while I'm kicking rocks.
Oh yeah, they pr'ed that they had angel investors to the tune of 5 or so million,
what happeNed to that?
IMO you all should stop studying L2 calling Mark, Dick, & Bob and ask them to get to work.
DPChicago
Share
Tuesday, October 12, 2010 10:56:34 AM
Re: boodlebing post# 7283 Post # of 7292
What does that even mean? CBIS' managementdoesnt have to do anything except wait for the vote. I am not expecting a PR. The vote to approve prop 19 is all the company needs.
So what is positive to say? I scrutinized very publicly released statement and draw my stance from performance and past precedence.
summary of the past 15 months of operations news. (35 releases I've concluded)
I disregarded and skipped over our companies statements of market conditions, filings, comments regarding other companies or other countries, and fluff.
Below this almost totally reads like a book of fiction - imo
6/18/2009….cbis…announced today that patent filings are expected for two of its key innovations. The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two, Dr. Mary J. Ruwart, Vice President, Research & Development explained. A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to invasion by a competing company
What HAppened?
7/02/2009…cbis...is pleased to announce that the company has retained Catalyst Xchange Corp. (CXC), located in London, Ontario, to provide it with investor relations services under an agreement dated June 30, 2009. Represented by its principals, Don Shaxon and Jason Springett, CXC will provide a variety of promotional and investor relations services to CSI, including assisting with the dissemination of news and information to the public, and, initiating and maintaining contact with investors. As part of its services CXC uses social networking and Internet-based marketing sites.
7/17/2009…cbis…is moving forward confidently under the guidance of its new President & CEO, Dr. Robert Melamede Ph.D. The planning for the companys product line up remains the same, including its FDA fast track initiatives. In the light of recent corporate management changes, Dr. Melamede has begun negotiating with high level industry executives to build a new team with both FDA protocol and research experience to work on Cannabis Sciences extensive product line up and rapid market entry initiatives
Should we discuss this bit of positive intelligence? Because some say, with force, That CBIS is non existent since the latest court findings is entirely retro active ...
7/20/2009….cbis….is moving forward with its preparations for a pre-IND meeting with the FDA, which will provide guidance on the manufacturing, non-clinical, and clinical development program for Cannabis Science Drugs.
As well the Company reports intentions to move corporate headquarters to Colorado Springs, Colorado. Dr. Melamede is currently in discussion with facilities in the Colorado Springs area.
7/24/2009…cbis…is making its anti-inflammatory formulation that targets influenza symptoms one of its top priority drugs to release, as the latest Swine flu numbers are rapidly increasing and have become quite alarming……The company is developing its strategy for studying the effects of its cannabis lozenge on influenza deaths that are associated with an excessive inflammatory response.
7/27/2009…cbis…to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medici
7/28/2009…cbis…the FDA has provided the Company with documentation to assist the Company to review and plan its initial applications to get its first drug into formal testing.
8/12/2009…cbis…has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials. The Company has determined it will have more than one product in clinical testing and trials at the same time…..The Company looks forward to announcing its continued progress with these initiatives through the development of an online progress chart that will become available at the www.cannabisscience.com website in the near future. This online tracking initiative will allow the general public immediate access to monitor each stage of development, submit questions, and request special circumstance information as we take our cannabis-based drugs to market.
8/31/2009….cbis….has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.
LOL
9/21/2009…cbis…is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.Robert Melamede stated, “After discussing our pharmaceutical products and initiatives with the FDA, Cannabis Science has taken certain steps to meet this potentially urgent situation. Although there is much yet to be done, I am very optimistic that we have an opportunity to have our products available to help meet this challenge.” Most importantly, we want everyone to understand the efficient and effective corporate structure that we are creating with holistic principles in mind. We are assembling teams in all the necessary arenas required for our growth and success. We have an agreement with a successful organic producer to provide us with the raw material. We are establishing a genetic testing facility to insure the production of consistent botanical products, as required for FDA approval, using state of the art procedures. We have identified a CGMP compliant processor who will make an FDA approvable extract for further processing by another qualified and experienced manufacturer, who will produce the final commercial product after FDA approval.
No update?
12/02/2009…cbis…it has settled pending litigation with K & D Equity Investments, Inc. and South Beach Live, Inc., and reached agreements with its largest creditors to convert their debt for shares…
nice EOY dilution, thanks.
12/15/2009…cbis…it has launched an Educational Series of Television commercials designed to inform its viewers about the importance of groundbreaking cannabis-based medicines. The Company is producing 10-15 different public service announcements in the series. Each one will cover a different topic, such as new break-through research developments, and tracking current and future cannabis medicines going through the FDA process. As well, the series will cover the commercialization of medical marijuana through licensed dispensaries, plus patient interviews about cannabis uses and life experiences, government legal issues and legalization progress tracking, as well as interviews with Doctors, patients, law makers and activists.
No one ever saw 1 of these.....
1/11/2010…cbis…is in negotiations with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.
Cannabis Science President & CEO, Dr. Robert Melamede, stated, "We are able to greatly accelerate our company's progress in the New Year by working with others doing research and sales for our cannabinoid medicines by entering into licensing agreements with them. We expect to have definitive agreements signed in the near future."……On January 25th as a part of its FDA Drug and new retail drug release initiatives the Company will be updating its new website to encompass the progress of each of its formulations to be released to the public through the FDA and other regulatory bodies. As well, the Company will be putting confidential patient surveys on its website. These confidential surveys are designed to produce information regarding how patients use cannabis for various medical conditions.
Update?
1/25/2010…cbis….released updates to its website today. The website www.cannabisscience.com now integrates its general public communications with recent and future developments in its analytical lab work, clinical research, and commercial production division that are in the process of formalizing the agreements with all the necessary contractors in order to move forward with its medical cannabis clinical trails…….The updated website includes new tools that allow its analytical, clinical research, and commercial production divisions to communicate with the medical cannabis community, survey specific populations, and receive feedback from patients, partners, and investors. The information gathered through its site surveys and forums will help guide its clinical research as well as contribute to scientific databases, and our live blog will allow the community to check in on its progress.
The blog and website are rotten with Nike Shoe spam....
2/09/2010….cbis….it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market….Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its cannabis based formulations for development, certain rights to manufacturing processes, and sales in each prospective jurisdiction and or country.
Didn't Happen?
2/22/2010….cbis….progress in its Analytical Lab Division at Cannabis Science. Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., explained, " As a patient oriented company located in a state with effective medical marijuana laws, we are able to study the medical production and use of cannabis in a variety of modalities. At the core of this research, we are working with patients producing top grade medical cannabis as the starting point for extracts and formulations to treat the many disease states that cannabinoids positively impact. Efficient, stable propagation and quality control of the starting material and downstream processes are essential to this progress."There are several integral and interdependent facets of this approach: Lab Division:I. Propagationa. Traditional Cloning, Micropropagation & Extensive Seed BankII. QC & Analyticsa. Genetic QC such as Fingerprintingb. Biochemical & Contaminant QC including HPLC and GCIII. Extracts and FormulationsIV. Final Product Testing a. Local clinical Trials b. FDA Clinical Trials
This is important boys and girls because our company has an analytical lab, much like the bat cave it doesn't exist....
2/25/2010…cbis….is pleased to report to their shareholders that the choice of our initial cannabis-based pharmaceutical for FDA clinical trials has been made. The Company has reported several possible drugs for FDA clinical trials. Based on extensive studies, the Company has decided to contract with a group based in Colorado to handle the Company’s FDA filings. Appropriate announcements will be made when the contracts are finalized.
Fluff that kept us longs biting......
5/7/2010….cbis….has opened an in-house investor relations and public relations department in South Florida. Mark J. Friedman, a friend of Cannabis Science President Dr. Melamede, will head up the newly established investor relations department with two of Mr. Friedman's associates helping to cover the phones to start. Mr. Friedman can be reached in the South Florida Investor Relations office at 1.877.431.CBIS (2247). The phone lines are open during regular business hours for investors and the general public to get timely information and instant updates on developments and questions concerning the Company.
5/12/2010….cbis….it is adding Online Communication Specialists in response to an increasing interest in Dr. Robert Melamede's understanding of the amazing roles played by the endocannabinoid system.
5/13/2009…cbis…it is in negotiations for a 7,500 square foot facility in Colorado Springs, CO that will allow the company to develop both research and revenues in compliance with state laws and federal guidelines….Richard Cowan, Cannabis Science CFO, concluded, "We are very pleased with the enormous media interest and the support we have received over the last few months from our increasing list of partners, patients & shareholders. Steady expansion in the Company has provided us with the exciting opportunity to negotiate for a new space in Colorado Springs, CO that will accommodate the upcoming operational expansions in the Company. The Company will be making very exciting announcements over the next few days outlining these new business expansions and relationships."
Did this happen? no update ever?
5/24/2010…cbis….it has acquired 100% of a private company with two revenue producing operations, an organic medical marijuana growing facility and a medical marijuana dispensary providing patients with medical marijuana in Colorado in accordance with state laws.
:(
6/01/2010…cbis…is pleased to announces preliminary patent disclosures and major steps towards the acquisition of a private company for the development of the new patentable products that should facilitate broad acceptance of specific Cannabis Science pharmaceutical products designed for the treatment of chronic pain, Post Traumatic Stress Disorder (PTSD) and other critical illnesses addressed throughout the www.cannabisscience.com company website….Melamede, PhD., Cannabis Science President and CEO, reported, "We have been negotiating to purchase a privately held biopharmaceutical company that owns complementary patented intellectual property for specific clinical stage cannabinoid products and uses. As a faculty member at the University of Colorado at Colorado Springs, I have filed a preliminary patent disclosure with the University of Colorado regarding additional new technology that Cannabis Science intends to develop through the targeted private company acquisition. As a part of this process, we are hiring a distinguished patent attorney to help with the University disclosure and ultimate patent filings. We are also using our FDA consultants to advise on the technology's FDA approval pathway because we foresee several new FDA pharmaceutical products that can be derived from this deal."
This was the last fluff we saw mention of FDA jibber jabber......
6/17/2010…cbis….is pleased to report that it is acquiring one of the leading medical marijuana providers and pioneers in the industry in the state of Montana; Montana Pain Management, Inc. (MPM) (www.montanapm.com). MPM is a for-profit clinic which, in conjunction with duly licensed caregivers, provides a full range of cannabis therapeutics and other services to its patients throughout the state of Montana
:(
6/29/2010….cbis….reports that it has begun the process of expanding the internal production and research capabilities of Missoula medical cannabis provider, Montana Pain Management (MPM), which Cannabis Science acquired earlier this month.
:(
7/06/2010….cbis….is proud to announce that Dr. Arturo Morales of Hartford, Connecticut, has agreed to join its Scientific Advisory Board. Dr. Robert Melamede PhD., Cannabis Science President and CEO noted, "We are extremely honored to have such a distinguished doctor join our Scientific Advisory Board. Dr. Morales has said that he wishes to become a 'successful advocate in the struggle to remove restrictions on the medical uses of cannabis.' We are delighted to welcome him to our team.
Does Dr. Morales still work here? DOes he have any interest in CBIS?
7/08/2010….cbis….it has entered into a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and producing medical cannabis for patients in compliance with the new Colorado laws regulating medical marijuana in the state.
Ah yeah, were still waiting for an update in this....
8/12/2010….cbis….announced today that it has executed a Joint Venture Agreement with Smokefree Innotec Inc. (Pink Sheets:SFIO). The objective of the joint venture is to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products. Under the joint venture, Smokefree Innotec, Inc. will provide its high-tech smoke-free vapor technology devices, and Cannabis Science will provide all the medical cannabis extract formulations. Both parties equally share in the revenues derived from this Joint Venture.
And does Rockbrook with full latitude have claim to this JV?
8/18/2010….cbis….reports that Cannabis Science sent an email to Mr. Rick Rosio on July 23, 2010 notifying him that he appeared to be in serious breach of the non-disclosure/non-circumvention agreement that he and Montana Pain Management, Inc. ("MPM") had signed with Cannabis Science. Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President and CEO said, "We are extremely disappointed that the actions taken by Mr. Rosio to deliberately breach a non-disclosure/non-circumvention agreement by contacting and conducting business with a scientific advisor of the Company, Dr. Arturo Morales. For Mr. Rosio to use that breach as the basis for Montana Pain Management to cancel the signed Share Purchase Agreement is even worse.
CBIS has not attempted to update or upgrade corporate non compete clauses....
8/18/2010….cbis….signed with RockBrook Inc., its first manufacturing and development license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.
Is this retroactive and apply to future FDA drugs? If so, ouch....
8/18/2010…cbis….Thomas Schroepfer, CEO, (www.sfio.us or http://www.realsmokefree.com) confirmed today the announcement by the Biotech company Cannabis Science (OTCBB:CBIS) regarding entering into a joint venture agreement to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products, as released by CBIS on August 13. He stated, “Pursuant to the joint venture, Smokefree Innotec Inc will supply its high-tech smoke-free vapor technology devices and Cannabis Science will provide all the medical cannabis extract formulations.”
I ask how will they get product (marijuana) from State to State? What were the terms and conditions of this JV? Will rockbrook intercept or have claim to proceeds?
8/24/2010….cbis….Dr. Robert Melamede, PhD., whose mother was German, remarked, "Germany's recognition of the medical value of cannabis coincides with our plans for expansion into Europe. We hope that America is not going to squander its lead in medical cannabis research, but Cannabis Science will certainly work with German and other European researchers and clinicians to develop medical cannabis products that meet the needs of patients around the world."
LOL...we publicly released heritage lineage...
8/30/2010…cbis….is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges…..cbis…..is vigorously seeking entry into the European medical cannabis market on the footsteps of GW Pharmaceuticals plc (GWPharm.com), a UK based commercial cannabinoid pharmaceutical company, which paved the way with the introduction and approval of its product, Sativex® in the UK and now Spain, which gave its regulatory approval on July 28, 2010. Currently Sativex® is approved in the UK and Spain as a prescription medicine for treatment of MS spasticity and in Canada for relief of neuropathic pain and advanced cancer pain.
9/09/2010….cbis….is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado.
What progress; Fill us in please...
9/13/2010…cbis….announces the formation of a new LLC, CANNABIS SCIENCE SMOKEFREE JV LLC, which has started testing various medical cannabis formulations for possible early JV product release entering the potential multi-billion medical cannabis market.
9/20/2010….cbis….is pleased to announce that its Board of Directors have begun investigating the corporate and legal requirements required to issue dividends to shareholders to create a new class of common shares. …..The company is in advanced negotiations with several groups pursuing funding opportunities for up to $5 million between $1.00 and $3.00 per new share. ……The proceeds will be used to fund FDA clinical trials, acquisitions, and further product research and development.
no, I wont just sell and move on it goes against my strategy,
But lets discuss what is positive with CBIS. I have posted many questions and sent those questions to the officers personal and business email, none have been answered.
But just for entertainment tonight lets review some positives...
So what is positive to say? I scrutinized very publicly released statement and draw my stance from performance and past precedence.
summary of the past 15 months of operations news. (35 releases I've concluded)
I disregarded and skipped over our companies statements of market conditions, filings, comments regarding other companies or other countries, and fluff.
Below this almost totally reads like a book of fiction - imo
6/18/2009….cbis…announced today that patent filings are expected for two of its key innovations. The Drug Development Team members recognize the importance of having our first cannabis-based medicine covered, not just by one patent, but by two, Dr. Mary J. Ruwart, Vice President, Research & Development explained. A competitor can sometimes engineer a way around a single patent. Patenting both the manufacturing process as well as the delivery system virtually guarantees that our product will be immune to invasion by a competing company
What HAppened?
7/02/2009…cbis...is pleased to announce that the company has retained Catalyst Xchange Corp. (CXC), located in London, Ontario, to provide it with investor relations services under an agreement dated June 30, 2009. Represented by its principals, Don Shaxon and Jason Springett, CXC will provide a variety of promotional and investor relations services to CSI, including assisting with the dissemination of news and information to the public, and, initiating and maintaining contact with investors. As part of its services CXC uses social networking and Internet-based marketing sites.
7/17/2009…cbis…is moving forward confidently under the guidance of its new President & CEO, Dr. Robert Melamede Ph.D. The planning for the companys product line up remains the same, including its FDA fast track initiatives. In the light of recent corporate management changes, Dr. Melamede has begun negotiating with high level industry executives to build a new team with both FDA protocol and research experience to work on Cannabis Sciences extensive product line up and rapid market entry initiatives
Should we discuss this bit of positive intelligence? Because some say, with force, That CBIS is non existent since the latest court findings is entirely retro active ...
7/20/2009….cbis….is moving forward with its preparations for a pre-IND meeting with the FDA, which will provide guidance on the manufacturing, non-clinical, and clinical development program for Cannabis Science Drugs.
As well the Company reports intentions to move corporate headquarters to Colorado Springs, Colorado. Dr. Melamede is currently in discussion with facilities in the Colorado Springs area.
7/24/2009…cbis…is making its anti-inflammatory formulation that targets influenza symptoms one of its top priority drugs to release, as the latest Swine flu numbers are rapidly increasing and have become quite alarming……The company is developing its strategy for studying the effects of its cannabis lozenge on influenza deaths that are associated with an excessive inflammatory response.
7/27/2009…cbis…to Apply to the FDA to Utilize Their Fast Track Procedures to Help Speed the Approval of Its Cannabinoid Medici
7/28/2009…cbis…the FDA has provided the Company with documentation to assist the Company to review and plan its initial applications to get its first drug into formal testing.
8/12/2009…cbis…has completed its review of the FDA licensing requirements and has made key progress with mapping out its initial cannabis drug medicines for FDA clinical trials. The Company has determined it will have more than one product in clinical testing and trials at the same time…..The Company looks forward to announcing its continued progress with these initiatives through the development of an online progress chart that will become available at the www.cannabisscience.com website in the near future. This online tracking initiative will allow the general public immediate access to monitor each stage of development, submit questions, and request special circumstance information as we take our cannabis-based drugs to market.
8/31/2009….cbis….has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.
LOL
9/21/2009…cbis…is pleased to report progress for its phytocannabinoid pharmaceutical products to help reduce ARDS-associated deaths from both the Avian and Swine Influenza infections.Robert Melamede stated, “After discussing our pharmaceutical products and initiatives with the FDA, Cannabis Science has taken certain steps to meet this potentially urgent situation. Although there is much yet to be done, I am very optimistic that we have an opportunity to have our products available to help meet this challenge.” Most importantly, we want everyone to understand the efficient and effective corporate structure that we are creating with holistic principles in mind. We are assembling teams in all the necessary arenas required for our growth and success. We have an agreement with a successful organic producer to provide us with the raw material. We are establishing a genetic testing facility to insure the production of consistent botanical products, as required for FDA approval, using state of the art procedures. We have identified a CGMP compliant processor who will make an FDA approvable extract for further processing by another qualified and experienced manufacturer, who will produce the final commercial product after FDA approval.
No update?
12/02/2009…cbis…it has settled pending litigation with K & D Equity Investments, Inc. and South Beach Live, Inc., and reached agreements with its largest creditors to convert their debt for shares…
nice EOY dilution, thanks.
12/15/2009…cbis…it has launched an Educational Series of Television commercials designed to inform its viewers about the importance of groundbreaking cannabis-based medicines. The Company is producing 10-15 different public service announcements in the series. Each one will cover a different topic, such as new break-through research developments, and tracking current and future cannabis medicines going through the FDA process. As well, the series will cover the commercialization of medical marijuana through licensed dispensaries, plus patient interviews about cannabis uses and life experiences, government legal issues and legalization progress tracking, as well as interviews with Doctors, patients, law makers and activists.
No one ever saw 1 of these.....
1/11/2010…cbis…is in negotiations with several companies in the US and internationally to contract or license its formulations for development, certain rights to manufacturing processes, and the sale in each prospective jurisdiction and or country.
Cannabis Science President & CEO, Dr. Robert Melamede, stated, "We are able to greatly accelerate our company's progress in the New Year by working with others doing research and sales for our cannabinoid medicines by entering into licensing agreements with them. We expect to have definitive agreements signed in the near future."……On January 25th as a part of its FDA Drug and new retail drug release initiatives the Company will be updating its new website to encompass the progress of each of its formulations to be released to the public through the FDA and other regulatory bodies. As well, the Company will be putting confidential patient surveys on its website. These confidential surveys are designed to produce information regarding how patients use cannabis for various medical conditions.
Update?
1/25/2010…cbis….released updates to its website today. The website www.cannabisscience.com now integrates its general public communications with recent and future developments in its analytical lab work, clinical research, and commercial production division that are in the process of formalizing the agreements with all the necessary contractors in order to move forward with its medical cannabis clinical trails…….The updated website includes new tools that allow its analytical, clinical research, and commercial production divisions to communicate with the medical cannabis community, survey specific populations, and receive feedback from patients, partners, and investors. The information gathered through its site surveys and forums will help guide its clinical research as well as contribute to scientific databases, and our live blog will allow the community to check in on its progress.
The blog and website are rotten with Nike Shoe spam....
2/09/2010….cbis….it is finalizing agreements with suppliers, manufactures, and research institutions that it expects will close within days and weeks to come. Once these agreements are closed they will be announced along with details on how CBIS will bring its first Cannabis based pharmaceutical products to market….Cannabis Science is in negotiations with several companies in the US and internationally to contract or license its cannabis based formulations for development, certain rights to manufacturing processes, and sales in each prospective jurisdiction and or country.
Didn't Happen?
2/22/2010….cbis….progress in its Analytical Lab Division at Cannabis Science. Cannabis Science Inc., President & CEO, Dr. Robert Melamede Ph.D., explained, " As a patient oriented company located in a state with effective medical marijuana laws, we are able to study the medical production and use of cannabis in a variety of modalities. At the core of this research, we are working with patients producing top grade medical cannabis as the starting point for extracts and formulations to treat the many disease states that cannabinoids positively impact. Efficient, stable propagation and quality control of the starting material and downstream processes are essential to this progress."There are several integral and interdependent facets of this approach: Lab Division:I. Propagationa. Traditional Cloning, Micropropagation & Extensive Seed BankII. QC & Analyticsa. Genetic QC such as Fingerprintingb. Biochemical & Contaminant QC including HPLC and GCIII. Extracts and FormulationsIV. Final Product Testing a. Local clinical Trials b. FDA Clinical Trials
This is important boys and girls because our company has an analytical lab, much like the bat cave it doesn't exist....
2/25/2010…cbis….is pleased to report to their shareholders that the choice of our initial cannabis-based pharmaceutical for FDA clinical trials has been made. The Company has reported several possible drugs for FDA clinical trials. Based on extensive studies, the Company has decided to contract with a group based in Colorado to handle the Company’s FDA filings. Appropriate announcements will be made when the contracts are finalized.
Fluff that kept us longs biting......
5/7/2010….cbis….has opened an in-house investor relations and public relations department in South Florida. Mark J. Friedman, a friend of Cannabis Science President Dr. Melamede, will head up the newly established investor relations department with two of Mr. Friedman's associates helping to cover the phones to start. Mr. Friedman can be reached in the South Florida Investor Relations office at 1.877.431.CBIS (2247). The phone lines are open during regular business hours for investors and the general public to get timely information and instant updates on developments and questions concerning the Company.
5/12/2010….cbis….it is adding Online Communication Specialists in response to an increasing interest in Dr. Robert Melamede's understanding of the amazing roles played by the endocannabinoid system.
5/13/2009…cbis…it is in negotiations for a 7,500 square foot facility in Colorado Springs, CO that will allow the company to develop both research and revenues in compliance with state laws and federal guidelines….Richard Cowan, Cannabis Science CFO, concluded, "We are very pleased with the enormous media interest and the support we have received over the last few months from our increasing list of partners, patients & shareholders. Steady expansion in the Company has provided us with the exciting opportunity to negotiate for a new space in Colorado Springs, CO that will accommodate the upcoming operational expansions in the Company. The Company will be making very exciting announcements over the next few days outlining these new business expansions and relationships."
Did this happen? no update ever?
5/24/2010…cbis….it has acquired 100% of a private company with two revenue producing operations, an organic medical marijuana growing facility and a medical marijuana dispensary providing patients with medical marijuana in Colorado in accordance with state laws.
:(
6/01/2010…cbis…is pleased to announces preliminary patent disclosures and major steps towards the acquisition of a private company for the development of the new patentable products that should facilitate broad acceptance of specific Cannabis Science pharmaceutical products designed for the treatment of chronic pain, Post Traumatic Stress Disorder (PTSD) and other critical illnesses addressed throughout the www.cannabisscience.com company website….Melamede, PhD., Cannabis Science President and CEO, reported, "We have been negotiating to purchase a privately held biopharmaceutical company that owns complementary patented intellectual property for specific clinical stage cannabinoid products and uses. As a faculty member at the University of Colorado at Colorado Springs, I have filed a preliminary patent disclosure with the University of Colorado regarding additional new technology that Cannabis Science intends to develop through the targeted private company acquisition. As a part of this process, we are hiring a distinguished patent attorney to help with the University disclosure and ultimate patent filings. We are also using our FDA consultants to advise on the technology's FDA approval pathway because we foresee several new FDA pharmaceutical products that can be derived from this deal."
This was the last fluff we saw mention of FDA jibber jabber......
6/17/2010…cbis….is pleased to report that it is acquiring one of the leading medical marijuana providers and pioneers in the industry in the state of Montana; Montana Pain Management, Inc. (MPM) (www.montanapm.com). MPM is a for-profit clinic which, in conjunction with duly licensed caregivers, provides a full range of cannabis therapeutics and other services to its patients throughout the state of Montana
:(
6/29/2010….cbis….reports that it has begun the process of expanding the internal production and research capabilities of Missoula medical cannabis provider, Montana Pain Management (MPM), which Cannabis Science acquired earlier this month.
:(
7/06/2010….cbis….is proud to announce that Dr. Arturo Morales of Hartford, Connecticut, has agreed to join its Scientific Advisory Board. Dr. Robert Melamede PhD., Cannabis Science President and CEO noted, "We are extremely honored to have such a distinguished doctor join our Scientific Advisory Board. Dr. Morales has said that he wishes to become a 'successful advocate in the struggle to remove restrictions on the medical uses of cannabis.' We are delighted to welcome him to our team.
Does Dr. Morales still work here? DOes he have any interest in CBIS?
7/08/2010….cbis….it has entered into a long-term lease on a 9,500 square foot facility in Denver, Colorado, that will become its corporate offices, as well as serving as a research facility for developing, testing, and producing medical cannabis for patients in compliance with the new Colorado laws regulating medical marijuana in the state.
Ah yeah, were still waiting for an update in this....
8/12/2010….cbis….announced today that it has executed a Joint Venture Agreement with Smokefree Innotec Inc. (Pink Sheets:SFIO). The objective of the joint venture is to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products. Under the joint venture, Smokefree Innotec, Inc. will provide its high-tech smoke-free vapor technology devices, and Cannabis Science will provide all the medical cannabis extract formulations. Both parties equally share in the revenues derived from this Joint Venture.
And does Rockbrook with full latitude have claim to this JV?
8/18/2010….cbis….reports that Cannabis Science sent an email to Mr. Rick Rosio on July 23, 2010 notifying him that he appeared to be in serious breach of the non-disclosure/non-circumvention agreement that he and Montana Pain Management, Inc. ("MPM") had signed with Cannabis Science. Dr. Robert Melamede, Ph. D., Cannabis Science Inc., President and CEO said, "We are extremely disappointed that the actions taken by Mr. Rosio to deliberately breach a non-disclosure/non-circumvention agreement by contacting and conducting business with a scientific advisor of the Company, Dr. Arturo Morales. For Mr. Rosio to use that breach as the basis for Montana Pain Management to cancel the signed Share Purchase Agreement is even worse.
CBIS has not attempted to update or upgrade corporate non compete clauses....
8/18/2010….cbis….signed with RockBrook Inc., its first manufacturing and development license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado. The licensing agreement grants RockBrook the full latitude and rights to manufacture, develop, produce, distribute, and sell products developed from, or based on Cannabis Science formulations, and delivery systems for the Cannabis Science Brand of Pharmaceutical Products and Cannabis Science Ailment Formulations within the State of Colorado.
Is this retroactive and apply to future FDA drugs? If so, ouch....
8/18/2010…cbis….Thomas Schroepfer, CEO, (www.sfio.us or http://www.realsmokefree.com) confirmed today the announcement by the Biotech company Cannabis Science (OTCBB:CBIS) regarding entering into a joint venture agreement to develop and market several high-tech smoke-free vaporized medical cannabis pharmaceutical products, as released by CBIS on August 13. He stated, “Pursuant to the joint venture, Smokefree Innotec Inc will supply its high-tech smoke-free vapor technology devices and Cannabis Science will provide all the medical cannabis extract formulations.”
I ask how will they get product (marijuana) from State to State? What were the terms and conditions of this JV? Will rockbrook intercept or have claim to proceeds?
8/24/2010….cbis….Dr. Robert Melamede, PhD., whose mother was German, remarked, "Germany's recognition of the medical value of cannabis coincides with our plans for expansion into Europe. We hope that America is not going to squander its lead in medical cannabis research, but Cannabis Science will certainly work with German and other European researchers and clinicians to develop medical cannabis products that meet the needs of patients around the world."
LOL...we publicly released heritage lineage...
8/30/2010…cbis….is pleased to announce that the Company is currently raising working capital in the European market and pursuing listings on the Frankfurt and other major European exchanges…..cbis…..is vigorously seeking entry into the European medical cannabis market on the footsteps of GW Pharmaceuticals plc (GWPharm.com), a UK based commercial cannabinoid pharmaceutical company, which paved the way with the introduction and approval of its product, Sativex® in the UK and now Spain, which gave its regulatory approval on July 28, 2010. Currently Sativex® is approved in the UK and Spain as a prescription medicine for treatment of MS spasticity and in Canada for relief of neuropathic pain and advanced cancer pain.
9/09/2010….cbis….is pleased with its progress with RockBrook Inc. as its first commercialization license for the Cannabis Science Brand of Pharmaceutical Products for the State of Colorado.
What progress; Fill us in please...
9/13/2010…cbis….announces the formation of a new LLC, CANNABIS SCIENCE SMOKEFREE JV LLC, which has started testing various medical cannabis formulations for possible early JV product release entering the potential multi-billion medical cannabis market.
9/20/2010….cbis….is pleased to announce that its Board of Directors have begun investigating the corporate and legal requirements required to issue dividends to shareholders to create a new class of common shares. …..The company is in advanced negotiations with several groups pursuing funding opportunities for up to $5 million between $1.00 and $3.00 per new share. ……The proceeds will be used to fund FDA clinical trials, acquisitions, and further product research and development.
Market Value1 $4,095,036 a/o Oct 08, 2010
Shares Outstanding 22,142,279 a/o Aug 20, 2009
Float 24,000,000 a/o Jun 17, 2010
Authorized Shares 250,000,000 a/o Jun 17, 2010
Par Value 0.0010
Booby said 95million
Thats 70million in less than 2 months....LOL....allegedly.....but thats not bad right.....LOL
http://www.otcmarkets.com/stock/CBIS/company-info
MJ a quick look at the latest filing should give us perspective on where volume at these low levels is sourced.
My guess is PHP holdings or Rcomm Inc. sole stockholder is hungry....
NOTE 3 STOCKHOLDERS’ EQUITY
On March 22, 2009 we entered into an agreement with Belmont Partners LLC (“Belmont”) by which Belmont acquired fifty three percent (53%) of our common stock. On March 24, 2009 we entered into an agreement with
Belmont and South Bay Financial Solutions Inc., (“South Bay”), pursuant to which South Bay acquired 50.01% of our total issued and outstanding common stock.
On March 24, 2009 we experienced a change of control as Belmont Partners LLC sold 10,114,774 shares of our common stock to South Bay Financial Solutions Inc.
On March 24, 2009, we issued one share of Series “A”, Convertible Preferred Stock to TDC Ventures LLC for the sum of $100.00.
On June 3, 2009 we issued Rcomm Inc. sole stockholder twenty million (20,000,000) shares of common stock in exchange of all Rcomm’s outstanding stocks. This was accounted for as a reverse merger acquisition having Rcomm, Inc. as the surviving entity.On June 9, 2009, we convert the sum of $436,177 of outstanding debt to Rovert Consulting Inc. into 2,180,885 shares of common stock.
On June 9, 2009, we convert the sum of $360,000 of outstanding debt due to Beach Cities Home Improvement Inc. into 1,800,000 shares of common stock.
On September 3, 2009 we acquired iMobilize Inc. in exchange for the issuance of four hundred twenty eight thousand five hundred seventy one (428,571) shares of common stock to iMobilize’s sole shareholder valued at $0.35 per share or $150,000.
On September 11, 2009 we convert the sum of $216,323 of outstanding debt to PHP Holdings Inc. into 2,704,042 shares of common stock.
On October 7, 2009 we converted the sum of $127,500 of outstanding debt to PHP Holdings Inc. into 1,500,000 shares of common stock.
On October 19, 2009 we converted the sum of $216,203 of outstanding debt to PHP Holdings Inc. into 3,088,616 shares of common stock.
On December 7, 2009 we converted the sum of $110,224 of outstanding debt to PHP Holdings Inc. into 3,325,000 shares of common stock.
On December 9, 2009 we converted the sum of $124,485 of outstanding debt to PHP Holdings Inc. into 3,755,190 shares of common stock.
On December 9, 2009 we converted the sum of $136,809 of outstanding debt to PHP Holdings Inc. into 4,126,954 shares of common stock.
On December 10, 2009 we converted the sum of $151,575 of outstanding debt to PHP Holdings Inc. into 4,572,408 shares of common stock.
On January 6, 2010 we converted the sum of $126,962 of outstanding debt to PHP Holdings Inc. into 5,520,077 shares of common stock.
On January 8, 2010 we converted the sum of $382,194 of outstanding debt to PHP Holdings Inc. into 6,066,564 shares of common stock.
On January 12, 2010 we converted the sum of $390,029 of outstanding debt to PHP Holdings Inc. into 6,667,154 shares of common stock.
On January 13, 2010 we converted the sum of $428,641 of outstanding debt to PHP Holdings Inc. into 7,327,202 shares of common stock.
On January 14, 2010 we converted the sum of $249,032 of outstanding debt to PHP Holdings Inc. into 6,385,441 shares of common stock.
On February 25, 2010 we converted the sum of $164,936 of outstanding debt to PHP Holdings Inc. into 9,664,226 shares of common stock.
On February 25, 2010 we converted the sum of $181,265 of outstanding debt to PHP Holdings Inc. into 10,620,984 shares of common stock.
On February 25, 2010 we converted the sum of $199,210 of outstanding debt to PHP Holdings Inc. into 11,672,461 shares of common stock.
On February 25, 2010 we converted the sum of $218,932 of outstanding debt to PHP Holdings Inc. into 12,828,035 shares of common stock.
On February 25, 2010 we converted the sum of $240,606 of outstanding debt to PHP Holdings Inc. into 14,098,011 shares of common stock.
On February 25, 2010 we converted $254,327 of outstanding debt to PHP Holdings Inc. into 14,901,989 shares of common stock.
On March 1, 2010 we converted the sum of $60,917 of outstanding debt to PHP Holdings Inc. into 5,000,000 shares of common stock.
On March 15, 2010 we converted the sum of $97,300 of outstanding debt to PHP Holdings Inc. into 13,900,000 shares of common stock.
The newly posted glossy brochures (that mysteriously appeared this weekend) listed our Share Structure
A/S 250,000,000
O/S 85,870,547
so the office has printed ANOTHER ten million and change...nice
CBIS has never diclosed a relationship with that fugative.
Maybe if mark comes to work tomorrow & answers the phone someone could verify...lol
should also try and verify how many shares they have printed lately
and verify the progress on That fathom headquaters (X2) and verify that they were going to update the web site and verify the FDA progress and verify sfio progress and verify rockbrook progress....just to name a few unverified loose ends....
instead of trying to speculate and read a penny stock chart like a ouiga board....
So can this comany that was supposed to simply supply PBR's but has now switched gears; into building the PBR's and growing material for/with customers harvest the material?
So what they can build & build...bigger & bigger...what are they going to do when the algae goose is cooked?
Not a healthy uptrend IMO
that's all. I'm happy for the support but
the holders sitting on +30% profit from last week
coupled with the some 30million swapped shares
coupled with the unknown dilution you know the office needs
created massive upward resistance to the tune of some mid to high tens of millions of shares
I hope I'm wrong, but haven't been proven wrong here yet
this needs to run 200-300% to get some of us longs back even
is mark working today?
Seriously, no one has asked this before?
BEHL doesn't have any means to harvest?
facepalm/
Ihub dump
has anyone spoken to marky mark and the funky bunch?
Without something substaintial from the office this support will be short lived.
Anyone check the share structure today?
rent is past due.
So we have some hundreds or hundreds of thousands of gallons of algae water?
Maybe that is why the basins are always filled with algae water; is there nothing else to do with it?
Thanks for the BNPD dividend update. It will be nice to see if BNPD produces funds this month
I have asked a question regarding harvesting that went unanswered: I will edit & repost it in the hopes someone will share......
So those pictures in the desert are promising that competent people are in the field.
They have set up shop and are poised to grow something in that ginormous bioreactor....
But I have an operational question....
So they grow algae
this time the bioreactor doesn't burst, leak, or fall apart
1.then what?
2. Have we seen an extraction (& or harvesting) process other than leaks or bursting equipment?
Is BEHL able to harvest and prepare algae for market?
3. Is "the market" in cue?
I ask these harvesting questions because I thought this was a bricks and mortar type deal; whereas BEHL manufactured algae bioreactors for customers.
4. Will or does BEHL also producing harvest equipment or a harvesting process?
TYIA
What happened to our BNPD dividend?
Just over 16million shares have traded under .05
I believe that almost double that amount will needed to be traded to break .10 if it is possible because
CBIS has issued 33,888,295 shares of stock since Aug 2009 to May 19, 2010
We don't know how many they have issued since the middle of May. I think around 20million more
The newly posted glossy brochures listed our Share Structure
A/S 250,000,000
O/S 85,870,547
The latest filing shows Share Structure
Bal, June 30, 2010 O/S 65,970,574
Thats an additional 20million+
So I see resistance of 50+million from the issuance of shares
and about 15-20 million from people that will flip out of CBIS under .10
So resistance of around 70million
CBIS will have to produce one great campaign to trade that many shares between now and Nov - imo, maybe mark can do it...I hope so....
Did anyone check the SS with the transfer Agent last week?
if not we should....
and 100% of the preferred shares are issued
High ere hi guys; Im lurking.
Im not a party crasher and hope the best for all of us.
I am praying that CBIS has something of substance to publicly release into your efforts;
a mainstream retail campaign would be a shot of vigor and I do not think they will get
a better opportunity.
Im not knocking and am thankful for the support, but, I am surprised the push didn't go further
I would have thought with all this mad accumulation we would have touched 7 or 8....
All this new accumulation will create resistance near $.25 as flipper ejects
(IF the push continues - imo - CBIS will ever see .50 again)
but my limits are set well over into dollar land as I am still hopeful
Monday is a trading day but trades won't settle till tuesday
Canada is closed till tuesday
GLTYA
O/S update: 2,190,044 from a cheerful & happy T/A
Pacing for new 52week high by EOY - IMO
nothing but good outlook here. I love my BX
Page II item 4. = our new controller
http://www.sec.gov/litigation/complaints/2008/comp20645_sniffex.pdf
I love getting in before the pump :)